Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment by Seini Moimoi | Mar 13, 2020 | Portfolio News
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights by Seini Moimoi | Mar 12, 2020 | Portfolio News
Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results by Seini Moimoi | Mar 12, 2020 | Portfolio News
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock by Seini Moimoi | Mar 10, 2020 | Portfolio News
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights by Seini Moimoi | Mar 10, 2020 | Portfolio News
